ArticleCancer chemotherapy and pharmacology2026

A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer.

Andrew Hudson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.